2023

1. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI

   Cardiovascular Drugs and Therapy, Vol. 37, Núm. 5, pp. 941-953

2. Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study

   The Lancet Regional Health - Europe, Vol. 31